dievini Hopp Biotech Holding

What dievini Hopp Biotech Holding does

dievini Hopp BioTech Holding GmbH & Co. KG is a privately held German investment holding company founded in 2005 and headquartered in Walldorf, Germany. The firm actively invests in and provides coaching support to Life and Health Sciences companies, with an investment focus on innovative therapeutics and diagnostics across oncology, neurology, infectious diseases, cell therapy, and drug delivery systems. The holding's portfolio comprises seven companies: AC Immune SA (precision medicine for neurodegenerative diseases), Cosmo Pharmaceuticals NV (GI disorders and endoscopic procedures), Heidelberg Pharma AG (antibody-targeted amanitin conjugates for oncology), Immatics N.V. (TCR-based cancer immunotherapies), Joimax GmbH (endoscopic minimally invasive spinal surgery systems), Molecular Health GmbH (precision medicine software via the Dataome platform), and Novaliq GmbH (water-free ocular therapeutics using the EyeSol platform).

The portfolio companies operate independently and generate revenue through distinct business models. Joimax has performed over 600,000 surgeries across approximately 50 countries with 25+ patent families and 240+ patents; Novaliq has secured three major regulatory approvals (MIEBO and VEVYE in the US in 2023, Vevizye in the EU in 2024) and partnered with Bausch + Lomb, Harrow, Théa, Senju, and Hengrui for global commercialization; Cosmo licenses Lialda, Uceris, and Winlevi through Giuliani, Shire, Salix/Valeant, Ferring, Glenmark, and InfectoPharm. Clinical-stage holdings (AC Immune, Immatics, Heidelberg Pharma) rely on partnerships with major pharma (Roche/Genentech, Eli Lilly, Janssen, Amgen, Genmab, BMS, GSK, Takeda) for development and commercialization.

dievini's revenue mechanics flow through equity appreciation and exits rather than direct product sales at the parent level. The firm also acquired LTS Lohmann Therapie-Systeme AG in July 2014, adding drug delivery exposure. The holding is controlled by the Hopp family — including Dietmar Hopp, co-founder of SAP — and is managed by a team including Oliver Hopp, Daniel Hopp, Dr. Mathias Hothum, Friedrich Bohlen, and Christof Hettich. Geographic investment activity is centered on Germany and Europe, while portfolio companies are supported in their global development and commercialization efforts.

Name

dievini Hopp Biotech Holding

Legal name

dievini Hopp BioTech holding GmbH & Co. KG

Website

https://www.dievini.de

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

dievini Hopp Biotech Holding is a privately held German investment holding company that invests in and coaches Life and Health Sciences companies developing innovative therapeutics and diagnostics across oncology, neurology, ophthalmology, GI disorders, and precision medicine.

Ownership category

akta.pro rank

Product category

Biotechnology Investment Holding

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Biotech investment holding
• Life sciences venture capital
• Health sciences equity investment
• Biopharmaceutical portfolio investment
• Medical technology investment

Headquarters

HQ city

Walldorf

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Investment Returns: dievini generates returns through equity investments in Life and Health Sciences companies, supporting management teams in corporate and business development to increase portfolio company value

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

dievini Hopp Biotech Holding is a private investment holding company that provides equity capital and active coaching to Life and Health Sciences companies with innovative therapeutics and diagnostics in oncology, neurology, infectious diseases, cell therapy, and drug delivery. It manages a portfolio of seven biopharmaceutical and medical technology companies and supports their global corporate and business development activities, with geographic focus centered on Germany and Europe.

Product overview

dievini Hopp BioTech holding is an active investment company in Life and Health Sciences. Rather than a single unified product, dievini manages a diversified portfolio of seven portfolio companies, each operating as independent biopharmaceutical or medical technology companies. The portfolio spans multiple therapeutic areas including oncology (Immatics, Heidelberg Pharma), neurodegenerative diseases (AC Immune), gastrointestinal disorders (Cosmo), ophthalmology (Novaliq), medical devices (Joimax), and precision medicine software (Molecular Health). dievini supports management teams in corporate and business development with focus on innovative therapeutics and diagnostics in oncology, neurology, infectious diseases, cell therapy, and drug delivery systems.

Differentiator

Problem solved

Functional benefit

Products and services

• Equity Investment in Life and Health Sciences Companies Provision of equity capital to innovative Life and Health Sciences companies with first-in-class and unique therapeutic and diagnostic approaches, with active coaching on corporate and business development for portfolio company management teams. Geographic focus on Germany and Europe, with portfolio companies supported in global development and commercialization.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

25 partnerships are on record, tiered major and minor.

• AmgenmajorStrategic or Co-development PartnerImmatics has partnered with Amgen for development of TCR-based immunotherapies as part of their partnered pipeline of 10 programs
• GenmabmajorStrategic or Co-development PartnerImmatics has partnered with Genmab for development of bispecific antibodies targeting cancer
• Bristol-Myers Squibb (BMS)majorStrategic or Co-development PartnerImmatics partnered with BMS for TCR-based cancer immunotherapies with $35 million equity investment made by BMS in 2023
• GSKmajorStrategic or Co-development PartnerImmatics has partnered with GSK for development of cancer immunotherapies
• TakedamajorStrategic or Co-development PartnerHeidelberg Pharma signed license agreement with Takeda for commercial development of an antibody-amanitin conjugate with an already selected target molecule
• Bausch + LombmajorChannel Partner/ Reseller/ DistributorBausch + Lomb acquired exclusive license for commercialization and development of NOV03 (perfluorohexyloctane) for dry eye disease in US and Canada. NOV03 approved as MIEBO in 2023.
• Jiangsu Hengrui MedicinemajorStrategic or Co-development PartnerNovaliq granted exclusive rights to Hengrui for development, manufacturing, and commercialization of NOV03 and CyclASol in China. Heng Qin approved as first treatment for dry eye disease associated with MGD in China in 2025.
• Laboratoires ThéamajorChannel Partner/ Reseller/ DistributorThéa acquired rights to commercialize Vevizye in Europe and selected MENA countries. EU approval received in 2024.
• Senju PharmaceuticalminorChannel Partner/ Reseller/ DistributorSenju Pharmaceutical licensed Japan rights to develop, manufacture, and commercialize NOV03 for dry eye disease
• HarrowmajorChannel Partner/ Reseller/ DistributorHarrow acquired US and Canadian commercial rights for VEVYE (cyclosporine ophthalmic solution) 0.1% from Novaliq. FDA approved May 2023.
• Genentech (Roche Group)majorStrategic or Co-development PartnerAC Immune has collaboration with Genentech for development of therapeutics for neurodegenerative diseases including crenezumab anti-Abeta antibody
• Eli Lilly and CompanymajorStrategic or Co-development PartnerAC Immune has strategic partnerships with Eli Lilly for precision medicine approaches to neurodegenerative diseases
• Janssen PharmaceuticalsmajorStrategic or Co-development PartnerAC Immune collaborates with Janssen on therapeutic and diagnostic programs for neurodegenerative diseases
• Life Molecular ImagingmajorStrategic or Co-development PartnerAC Immune partnered with Life Molecular Imaging for development and commercialization of PI-2620 Tau PET tracer for Alzheimer's disease. Phase 3 trial initiated.
• CharitémajorStrategic or Co-development PartnerMolecular Health collaborates with Charité for precision medicine applications and clinical data analysis
• M.D. Anderson Cancer CentermajorStrategic or Co-development PartnerMolecular Health collaborates with M.D. Anderson for cancer research and precision medicine development
• U.S. Food and Drug Administration (FDA)majorStrategic or Co-development PartnerMolecular Health collaborates with FDA on regulatory science and precision medicine standards
• GiulianimajorChannel Partner/ Reseller/ DistributorCosmo's Lialda/Mezavant/Mesavancol licensed globally to Giuliani for IBD treatment
• Shire LimitedmajorChannel Partner/ Reseller/ DistributorCosmo's Lialda/Mezavant/Mesavancol licensed to Shire Limited
• Salix/ValeantmajorChannel Partner/ Reseller/ DistributorCosmo's Uceris licensed in US to Salix/Valeant for induction of remission in ulcerative colitis
• FerringmajorChannel Partner/ Reseller/ DistributorCosmo's Cortiment licensed to Ferring for Rest of World markets
• MedtronicmajorStrategic or Co-development PartnerCosmo's subsidiary Cosmo Intelligent Medical Devices (IMD) expanded collaboration with Medtronic for GI Genius AI development
• GlenmarkmajorChannel Partner/ Reseller/ DistributorGlenmark launched Winlevi in key European markets following European Commission approval
• InfectoPharmmajorChannel Partner/ Reseller/ DistributorInfectoPharm launched Winlevi in Austria and Germany since June 2026
• Royal College of Surgeons of Edinburgh (RCSEd)majorStrategic or Co-development PartnerJoimax established ESPINEA academy in cooperation with RCSEd for surgeon training and competence development with CME-certified courses

Scale indicators2 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• OrbiMed: Global healthcare investment firm across private and public markets, venture through growth; comparable diversified approach to life sciences investing with strong presence in European biotech.
• Novo Holdings: Holding company of the Novo Nordisk Foundation, making long-term equity investments in life sciences companies globally; similar permanent-capital family/foundation structure backing biotech innovation.

Regional players

• Wellington Partners: European venture capital firm with deep life sciences practice investing in German and broader EU biotech companies; directly comparable in geographic concentration and therapeutic-area diversification.

Direct peers

• BB Biotech AG: Swiss-listed investment company focused on biotech equities, with a similar structure of holding diversified public and private biotech positions to capture long-term value creation in the sector.
• HBM Healthcare Investments: Swiss investment company that holds a diversified portfolio of public and private healthcare and biotech companies, sharing dievini's model of long-term holdings across development stages and therapeutic areas.
• Forbion: European life sciences venture capital firm investing across therapeutic areas and modalities; comparable in geographic focus (Europe), sector specialization (life sciences), and active portfolio support model.
• LSP (Life Sciences Partners): Amsterdam-based life sciences investment firm with a long track record of building and supporting European biotech companies; directly comparable in focus on European therapeutic platforms and patient-capital approach.
• Baker Bros. Advisors: US biotech-focused investment firm with concentrated long-term holdings in clinical-stage companies; comparable thesis of identifying differentiated science and supporting through clinical development.
• TVM Capital Healthcare: Transatlantic healthcare and life sciences investment firm with active European operations; comparable in backing mid- and late-stage therapeutic companies with operational support.
• Sofinnova Partners: European life sciences venture capital firm specializing in therapeutic and biotech investments; similar geographic profile and active-coaching investment approach for portfolio companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments19 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about dievini Hopp Biotech Holding